Healthcare Mergers, Acquisitions & Ventures Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions & Ventures Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Atrial Fibrillation
Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - the RE-LY(TM) Study
February 2nd, 2008
Boehringer Ingelheim announced that enrollment is complete for the landmark RE-LY trial to evaluate the long-term efficacy and safety of investigational oral direct thrombin inhibitor dabigatran etexilate for the prevention of stroke and systemic embolism in patients with atrial fibrillation. RE-LY (Randomized Evaluation of Long Term Anticoagulant Therapy) is the largest stroke prevention in atrial fibrillation trial conducted to date, with 18,114 patients, in 1,000 centers in 44 countries worldwide enrolled between December 2005 and December 2007. Currently, more than 10,000 patients have been treated for at least 6 months with final study results expected to be reported in early...
Source: Healthcare Mergers, Acquisitions & Ventures Week (2008-02-02)
|
